AstraZeneca Korea acquired an approval for the asthma and COPD inhaler ‘Symbicort Rapihaler’
The AstraZeneca Korea’s(President Liz Chatwin) asthma and chronic obstructive pulmonary disease(COPD) treatment ‘Symbicort Rapihaler(budesonide + formoterol)’ has recently been approved from the Ministry of Food and Drug Safety.
The recently-approved ‘Symbicort Rapihaler,’ a ICS/LABA(inhaled cor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
